The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA
Proliferating cell nuclear antigen (PCNA) plays an essential role in regulating DNA synthesis and repair and is indispensable to cancer cell growth and survival. We previously reported a novel cancer associated PCNA isoform (dubbed caPCNA), which was ubiquitously expressed in a broad range of cancer...
Saved in:
| Published in | Clinical cancer research Vol. 24; no. 23; pp. 6053 - 6065 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
01.12.2018
|
| Online Access | Get full text |
Cover
Loading…
| Abstract | Proliferating cell nuclear antigen (PCNA) plays an essential role in regulating DNA synthesis and repair and is indispensable to cancer cell growth and survival. We previously reported a novel cancer associated PCNA isoform (dubbed caPCNA), which was ubiquitously expressed in a broad range of cancer cells and tumor tissues, but not significantly in nonmalignant cells. We found the L126-Y133 region of caPCNA is structurally altered and more accessible to protein-protein interaction. A cell-permeable peptide harboring the L126-Y133 sequence blocked PCNA interaction in cancer cells and selectively kills cancer cells and xenograft tumors. On the basis of these findings, we sought small molecules targeting this peptide region as potential broad-spectrum anticancer agents.
By computer modeling and medicinal chemistry targeting a surface pocket partly delineated by the L126-Y133 region of PCNA, we identified a potent PCNA inhibitor (AOH1160) and characterized its therapeutic properties and potential toxicity.
AOH1160 selectively kills many types of cancer cells at below micromolar concentrations without causing significant toxicity to a broad range of nonmalignant cells. Mechanistically, AOH1160 interferes with DNA replication, blocks homologous recombination-mediated DNA repair, and causes cell-cycle arrest. It induces apoptosis in cancer cells and sensitizes them to cisplatin treatment. AOH1160 is orally available to animals and suppresses tumor growth in a dosage form compatible to clinical applications. Importantly, it does not cause significant toxicity at 2.5 times of an effective dose.
These results demonstrated the favorable therapeutic properties and the potential of AOH1160 as a broad-spectrum therapeutic agent for cancer treatment. |
|---|---|
| AbstractList | Proliferating cell nuclear antigen (PCNA) plays an essential role in regulating DNA synthesis and repair and is indispensable to cancer cell growth and survival. We previously reported a novel cancer associated PCNA isoform (dubbed caPCNA), which was ubiquitously expressed in a broad range of cancer cells and tumor tissues, but not significantly in nonmalignant cells. We found the L126-Y133 region of caPCNA is structurally altered and more accessible to protein-protein interaction. A cell-permeable peptide harboring the L126-Y133 sequence blocked PCNA interaction in cancer cells and selectively kills cancer cells and xenograft tumors. On the basis of these findings, we sought small molecules targeting this peptide region as potential broad-spectrum anticancer agents.
By computer modeling and medicinal chemistry targeting a surface pocket partly delineated by the L126-Y133 region of PCNA, we identified a potent PCNA inhibitor (AOH1160) and characterized its therapeutic properties and potential toxicity.
AOH1160 selectively kills many types of cancer cells at below micromolar concentrations without causing significant toxicity to a broad range of nonmalignant cells. Mechanistically, AOH1160 interferes with DNA replication, blocks homologous recombination-mediated DNA repair, and causes cell-cycle arrest. It induces apoptosis in cancer cells and sensitizes them to cisplatin treatment. AOH1160 is orally available to animals and suppresses tumor growth in a dosage form compatible to clinical applications. Importantly, it does not cause significant toxicity at 2.5 times of an effective dose.
These results demonstrated the favorable therapeutic properties and the potential of AOH1160 as a broad-spectrum therapeutic agent for cancer treatment. Proliferating cell nuclear antigen (PCNA) plays an essential role in regulating DNA synthesis and repair and is indispensable to cancer cell growth and survival. We previously reported a novel cancer associated PCNA isoform (dubbed caPCNA), which was ubiquitously expressed in a broad range of cancer cells and tumor tissues, but not significantly in nonmalignant cells. We found the L126-Y133 region of caPCNA is structurally altered and more accessible to protein-protein interaction. A cell-permeable peptide harboring the L126-Y133 sequence blocked PCNA interaction in cancer cells and selectively kills cancer cells and xenograft tumors. On the basis of these findings, we sought small molecules targeting this peptide region as potential broad-spectrum anticancer agents.PURPOSEProliferating cell nuclear antigen (PCNA) plays an essential role in regulating DNA synthesis and repair and is indispensable to cancer cell growth and survival. We previously reported a novel cancer associated PCNA isoform (dubbed caPCNA), which was ubiquitously expressed in a broad range of cancer cells and tumor tissues, but not significantly in nonmalignant cells. We found the L126-Y133 region of caPCNA is structurally altered and more accessible to protein-protein interaction. A cell-permeable peptide harboring the L126-Y133 sequence blocked PCNA interaction in cancer cells and selectively kills cancer cells and xenograft tumors. On the basis of these findings, we sought small molecules targeting this peptide region as potential broad-spectrum anticancer agents.By computer modeling and medicinal chemistry targeting a surface pocket partly delineated by the L126-Y133 region of PCNA, we identified a potent PCNA inhibitor (AOH1160) and characterized its therapeutic properties and potential toxicity.EXPERIMENTAL DESIGNBy computer modeling and medicinal chemistry targeting a surface pocket partly delineated by the L126-Y133 region of PCNA, we identified a potent PCNA inhibitor (AOH1160) and characterized its therapeutic properties and potential toxicity.AOH1160 selectively kills many types of cancer cells at below micromolar concentrations without causing significant toxicity to a broad range of nonmalignant cells. Mechanistically, AOH1160 interferes with DNA replication, blocks homologous recombination-mediated DNA repair, and causes cell-cycle arrest. It induces apoptosis in cancer cells and sensitizes them to cisplatin treatment. AOH1160 is orally available to animals and suppresses tumor growth in a dosage form compatible to clinical applications. Importantly, it does not cause significant toxicity at 2.5 times of an effective dose.RESULTSAOH1160 selectively kills many types of cancer cells at below micromolar concentrations without causing significant toxicity to a broad range of nonmalignant cells. Mechanistically, AOH1160 interferes with DNA replication, blocks homologous recombination-mediated DNA repair, and causes cell-cycle arrest. It induces apoptosis in cancer cells and sensitizes them to cisplatin treatment. AOH1160 is orally available to animals and suppresses tumor growth in a dosage form compatible to clinical applications. Importantly, it does not cause significant toxicity at 2.5 times of an effective dose.These results demonstrated the favorable therapeutic properties and the potential of AOH1160 as a broad-spectrum therapeutic agent for cancer treatment.CONCLUSIONSThese results demonstrated the favorable therapeutic properties and the potential of AOH1160 as a broad-spectrum therapeutic agent for cancer treatment. |
| Author | Hickey, Robert J. Hu, Weidong Cui, Qi Chen, Yuan Shi, Yanhong Yakushijin, Fumiko Sun, Emily Malkas, Linda H. Horne, David Lingeman, Robert Chao, Jianfei Gu, Long Stark, Jeremy M. Yuan, Yate-Ching Synold, Timothy W. Li, Hongzhi Reckamp, Karen L. Vonderfecht, Steven L. |
| Author_xml | – sequence: 1 givenname: Long surname: Gu fullname: Gu, Long – sequence: 2 givenname: Robert surname: Lingeman fullname: Lingeman, Robert – sequence: 3 givenname: Fumiko surname: Yakushijin fullname: Yakushijin, Fumiko – sequence: 4 givenname: Emily surname: Sun fullname: Sun, Emily – sequence: 5 givenname: Qi surname: Cui fullname: Cui, Qi – sequence: 6 givenname: Jianfei surname: Chao fullname: Chao, Jianfei – sequence: 7 givenname: Weidong surname: Hu fullname: Hu, Weidong – sequence: 8 givenname: Hongzhi surname: Li fullname: Li, Hongzhi – sequence: 9 givenname: Robert J. surname: Hickey fullname: Hickey, Robert J. – sequence: 10 givenname: Jeremy M. surname: Stark fullname: Stark, Jeremy M. – sequence: 11 givenname: Yate-Ching surname: Yuan fullname: Yuan, Yate-Ching – sequence: 12 givenname: Yuan surname: Chen fullname: Chen, Yuan – sequence: 13 givenname: Steven L. surname: Vonderfecht fullname: Vonderfecht, Steven L. – sequence: 14 givenname: Timothy W. surname: Synold fullname: Synold, Timothy W. – sequence: 15 givenname: Yanhong surname: Shi fullname: Shi, Yanhong – sequence: 16 givenname: Karen L. orcidid: 0000-0002-9213-0325 surname: Reckamp fullname: Reckamp, Karen L. – sequence: 17 givenname: David surname: Horne fullname: Horne, David – sequence: 18 givenname: Linda H. surname: Malkas fullname: Malkas, Linda H. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29967249$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kE9PwyAYh4mZcX_0I2h69MIsUOgaT0vjdMmiRueZAKUTQ9sJ1GTfXpZtFw-e-B2e3_vyPmMwaLtWA3CN0ilCdHaH0nwG04zgaVm-QRQzLfAZGCFKc0gwo4OYT8wQjL3_SlOUoTS7AENcFCzHWTECy_WnTuZtMEq0SrtkroL5MWGXdHUikoVxPkDTQmWF98l7I6yFTWe16q1O1sJtdDDtJnktn-eX4LwW1uur4zsBH4uHdfkEVy-Py3K-gopQFiCrBJa4YJJSUlezSslMSoEYE7lEuI7_I4SiSuWaoaqiRGoscF1nM6mViACZgNvD3K3rvnvtA2-MV9pa0equ9xynjOSoIAWN6M0R7WWjK751phFux0_nR-D-ACjXee90zZUJIpiuDU4Yy1HK97L5XiTfi-RRNkcxR9mxTf-0Twv-7_0CLv6Byw |
| CitedBy_id | crossref_primary_10_3390_ijms232214054 crossref_primary_10_1002_tox_23007 crossref_primary_10_1016_j_drudis_2024_104203 crossref_primary_10_1007_s10989_023_10512_7 crossref_primary_10_1016_j_chembiol_2022_10_005 crossref_primary_10_1371_journal_pone_0223894 crossref_primary_10_3390_biom11020129 crossref_primary_10_1186_s40164_024_00586_4 crossref_primary_10_3389_fcell_2019_00174 crossref_primary_10_3390_molecules29112630 crossref_primary_10_2139_ssrn_4065076 crossref_primary_10_3390_cancers14225546 crossref_primary_10_3892_mmr_2019_10735 crossref_primary_10_1097_CAD_0000000000000817 crossref_primary_10_1021_acs_jmedchem_4c00526 crossref_primary_10_1016_j_chembiol_2023_07_001 crossref_primary_10_2174_1568009620666200115162814 crossref_primary_10_1002_jmv_29244 crossref_primary_10_1016_j_canlet_2020_01_008 crossref_primary_10_2147_DDDT_S277160 crossref_primary_10_3390_v16081264 crossref_primary_10_1080_21655979_2022_2051805 crossref_primary_10_1021_jacs_2c06449 crossref_primary_10_1016_j_celrep_2023_112296 crossref_primary_10_3389_fonc_2021_822500 crossref_primary_10_1089_hum_2019_134 crossref_primary_10_1186_s12864_024_10834_w |
| Cites_doi | 10.1002/pros.21291 10.1007/978-1-62703-236-0_12 10.1371/journal.pone.0094773 10.1002/jcc.20289 10.1038/ncomms10637 10.1074/jbc.M106990200 10.1158/0008-5472.CAN-09-2687 10.1002/pmic.200600142 10.1371/journal.pone.0036248 10.1074/jbc.M111.309252 10.1016/j.bmcl.2006.05.025 10.1016/j.ebiom.2015.11.016 10.1200/JCO.2002.20.3.719 10.1371/journal.pone.0070430 10.1016/S1470-2045(12)70490-4 10.1093/aob/mcq243 10.1007/s00280-005-1027-y 10.1056/NEJMoa1210093 10.1016/0092-8674(94)90014-0 10.1038/emboj.2011.27 10.1002/1097-0142(19930601)71:11<3552::AID-CNCR2820711115>3.0.CO;2-N 10.1021/jm051256o 10.1038/369574a0 10.1038/nrc1951 10.1042/BST0370605 10.1371/journal.pbio.1000507 10.1158/1535-7163.MCT-10-0778 10.1074/jbc.M112.353201 10.1016/j.cell.2008.08.030 10.1124/mol.112.077735 10.1021/ja0100120 10.1056/NEJMoa1110557 10.1634/theoncologist.9-suppl_3-10 10.1371/journal.pone.0061362 10.1002/prp2.149 10.1371/journal.pgen.1000110 10.1016/S0304-3835(98)00118-9 10.1038/sj.onc.1201072 10.1124/dmd.105.004929 10.1073/pnas.0604614103 10.1056/NEJMoa0905360 10.1007/s00280-014-2574-x 10.1093/nar/gkp705 10.1124/mol.114.093211 10.1016/j.molimm.2012.09.012 |
| ContentType | Journal Article |
| Copyright | 2018 American Association for Cancer Research. |
| Copyright_xml | – notice: 2018 American Association for Cancer Research. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1158/1078-0432.CCR-18-0592 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-3265 |
| EndPage | 6065 |
| ExternalDocumentID | 29967249 10_1158_1078_0432_CCR_18_0592 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA120954 – fundername: NCI NIH HHS grantid: R01 CA121289 |
| GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV NPM RHF 7X8 |
| ID | FETCH-LOGICAL-c356t-6da2b296b553fd8dcb4bba166a7b12f1043351dc7e61dd53be2a2ff48beca12f3 |
| ISSN | 1078-0432 1557-3265 |
| IngestDate | Fri Jul 11 11:30:07 EDT 2025 Wed Feb 19 02:43:42 EST 2025 Thu Apr 24 22:58:23 EDT 2025 Tue Jul 01 01:30:16 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 23 |
| Language | English |
| License | 2018 American Association for Cancer Research. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c356t-6da2b296b553fd8dcb4bba166a7b12f1043351dc7e61dd53be2a2ff48beca12f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-9213-0325 |
| OpenAccessLink | https://clincancerres.aacrjournals.org/content/clincanres/24/23/6053.full.pdf |
| PMID | 29967249 |
| PQID | 2063719395 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2063719395 pubmed_primary_29967249 crossref_citationtrail_10_1158_1078_0432_CCR_18_0592 crossref_primary_10_1158_1078_0432_CCR_18_0592 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-12-01 2018-Dec-01 20181201 |
| PublicationDateYYYYMMDD | 2018-12-01 |
| PublicationDate_xml | – month: 12 year: 2018 text: 2018-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical cancer research |
| PublicationTitleAlternate | Clin Cancer Res |
| PublicationYear | 2018 |
| References | Tahan (2022061100595989400_bib3) 1993; 71 Lang (2022061100595989400_bib20) 2012; 7 Rufer (2022061100595989400_bib26) 2006; 34 Brown (2022061100595989400_bib19) 2009; 69 Flaherty (2022061100595989400_bib37) 2012; 367 Verstovsek (2022061100595989400_bib39) 2012; 366 Raschle (2022061100595989400_bib32) 2008; 134 Punchihewa (2022061100595989400_bib16) 2012; 287 Gu (2022061100595989400_bib25) 2015; 2 Friesner (2022061100595989400_bib17) 2006; 49 Fridman (2022061100595989400_bib30) 2010; 8 Tan (2022061100595989400_bib46) 2012; 81 Malkas (2022061100595989400_bib10) 2006; 103 Morton (2022061100595989400_bib33) 2000; 60 Foucquier (2022061100595989400_bib24) 2015; 3 Warbrick (2022061100595989400_bib9) 1997; 14 Al-Minawi (2022061100595989400_bib31) 2009; 37 Savjani (2022061100595989400_bib35) 2012; 2012 Wang (2022061100595989400_bib12) 2011; 71 Izbicka (2022061100595989400_bib43) 2005; 6 Yu (2022061100595989400_bib47) 2013; 8 Muller (2022061100595989400_bib45) 2013; 8 Aaltomaa (2022061100595989400_bib1) 1993; 13 Waga (2022061100595989400_bib7) 1994; 369 Shoemaker (2022061100595989400_bib28) 2006; 6 Bennardo (2022061100595989400_bib21) 2008; 4 Garcia-Vallejo (2022061100595989400_bib44) 2013; 53 Strzalka (2022061100595989400_bib4) 2011; 107 Smith (2022061100595989400_bib11) 2015; 87 Phillips (2022061100595989400_bib18) 2005; 26 Gunn (2022061100595989400_bib22) 2011; 286 Vogel (2022061100595989400_bib40) 2002; 20 Zhao (2022061100595989400_bib48) 2011; 10 Frum (2022061100595989400_bib23) 2013; 962 Gu (2022061100595989400_bib14) 2014; 9 Shibata (2022061100595989400_bib27) 2011; 30 Stoimenov (2022061100595989400_bib5) 2009; 37 Cui (2022061100595989400_bib49) 2016; 7 Morton (2022061100595989400_bib34) 2005; 56 Burris (2022061100595989400_bib36) 2004; 9 Ducoux (2022061100595989400_bib8) 2001; 276 Chu (2022061100595989400_bib2) 1998; 131 Krishna (2022061100595989400_bib6) 1994; 79 Santoro (2022061100595989400_bib38) 2013; 14 Von Hoff (2022061100595989400_bib41) 2009; 361 Konkel (2022061100595989400_bib42) 2006; 16 Mayer (2022061100595989400_bib29) 2001; 123 Hoelz (2022061100595989400_bib13) 2006; 6 Lingeman (2022061100595989400_bib15) 2014; 74 |
| References_xml | – volume: 71 start-page: 748 year: 2011 ident: 2022061100595989400_bib12 article-title: Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer publication-title: Prostate doi: 10.1002/pros.21291 – volume: 962 start-page: 147 year: 2013 ident: 2022061100595989400_bib23 article-title: Use of the DNA fiber spreading technique to detect the effects of mutant p53 on DNA replication publication-title: Methods Mol Biol doi: 10.1007/978-1-62703-236-0_12 – volume: 9 start-page: e94773 year: 2014 ident: 2022061100595989400_bib14 article-title: A PCNA-derived cell permeable peptide selectively inhibits neuroblastoma cell growth publication-title: PLoS One doi: 10.1371/journal.pone.0094773 – volume: 26 start-page: 1781 year: 2005 ident: 2022061100595989400_bib18 article-title: Scalable molecular dynamics with NAMD publication-title: J Comput Chem doi: 10.1002/jcc.20289 – volume: 7 start-page: 10637 year: 2016 ident: 2022061100595989400_bib49 article-title: Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis publication-title: Nat Commun doi: 10.1038/ncomms10637 – volume: 276 start-page: 49258 year: 2001 ident: 2022061100595989400_bib8 article-title: Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA replication through a conserved p21(Cip1)-like PCNA-binding motif present in the third subunit of human DNA polymerase delta publication-title: J Biol Chem doi: 10.1074/jbc.M106990200 – volume: 69 start-page: 8886 year: 2009 ident: 2022061100595989400_bib19 article-title: Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-2687 – volume: 6 start-page: 4808 year: 2006 ident: 2022061100595989400_bib13 article-title: The discovery of labile methyl esters on proliferating cell nuclear antigen by MS/MS publication-title: Proteomics doi: 10.1002/pmic.200600142 – volume: 7 start-page: e36248 year: 2012 ident: 2022061100595989400_bib20 article-title: Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells publication-title: PLoS One doi: 10.1371/journal.pone.0036248 – volume: 286 start-page: 42470 year: 2011 ident: 2022061100595989400_bib22 article-title: Correct end use during end joining of multiple chromosomal double strand breaks is influenced by repair protein RAD50, DNA-dependent protein kinase DNA-PKcs, and transcription context publication-title: J Biol Chem doi: 10.1074/jbc.M111.309252 – volume: 16 start-page: 3950 year: 2006 ident: 2022061100595989400_bib42 article-title: Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2006.05.025 – volume: 2012 start-page: 195727 year: 2012 ident: 2022061100595989400_bib35 article-title: Drug solubility: importance and enhancement techniques publication-title: ISRN Pharm – volume: 2 start-page: 1923 year: 2015 ident: 2022061100595989400_bib25 article-title: The mechanism by which MYCN amplification confers an enhanced sensitivity to a PCNA-derived cell permeable peptide in neuroblastoma cells publication-title: EBioMedicine doi: 10.1016/j.ebiom.2015.11.016 – volume: 20 start-page: 719 year: 2002 ident: 2022061100595989400_bib40 article-title: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.3.719 – volume: 8 start-page: e70430 year: 2013 ident: 2022061100595989400_bib45 article-title: Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells publication-title: PLoS One doi: 10.1371/journal.pone.0070430 – volume: 14 start-page: 55 year: 2013 ident: 2022061100595989400_bib38 article-title: Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70490-4 – volume: 107 start-page: 1127 year: 2011 ident: 2022061100595989400_bib4 article-title: Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation publication-title: Ann Bot doi: 10.1093/aob/mcq243 – volume: 6 start-page: 1200 year: 2005 ident: 2022061100595989400_bib43 article-title: Therapeutic strategies for the treatment of neuroblastoma publication-title: Curr Opin Investig Drugs – volume: 56 start-page: 629 year: 2005 ident: 2022061100595989400_bib34 article-title: Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-005-1027-y – volume: 367 start-page: 1694 year: 2012 ident: 2022061100595989400_bib37 article-title: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations publication-title: N Engl J Med doi: 10.1056/NEJMoa1210093 – volume: 79 start-page: 1233 year: 1994 ident: 2022061100595989400_bib6 article-title: Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA publication-title: Cell doi: 10.1016/0092-8674(94)90014-0 – volume: 30 start-page: 1079 year: 2011 ident: 2022061100595989400_bib27 article-title: Factors determining DNA double-strand break repair pathway choice in G2 phase publication-title: EMBO J doi: 10.1038/emboj.2011.27 – volume: 71 start-page: 3552 year: 1993 ident: 2022061100595989400_bib3 article-title: Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score publication-title: Cancer doi: 10.1002/1097-0142(19930601)71:11<3552::AID-CNCR2820711115>3.0.CO;2-N – volume: 49 start-page: 6177 year: 2006 ident: 2022061100595989400_bib17 article-title: Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes publication-title: J Med Chem doi: 10.1021/jm051256o – volume: 369 start-page: 574 year: 1994 ident: 2022061100595989400_bib7 article-title: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA publication-title: Nature doi: 10.1038/369574a0 – volume: 60 start-page: 4206 year: 2000 ident: 2022061100595989400_bib33 article-title: Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase publication-title: Cancer Res – volume: 6 start-page: 813 year: 2006 ident: 2022061100595989400_bib28 article-title: The NCI60 human tumour cell line anticancer drug screen publication-title: Nat Rev Cancer doi: 10.1038/nrc1951 – volume: 37 start-page: 605 year: 2009 ident: 2022061100595989400_bib5 article-title: PCNA on the crossroad of cancer publication-title: Biochem Soc Trans doi: 10.1042/BST0370605 – volume: 8 start-page: e1000507 year: 2010 ident: 2022061100595989400_bib30 article-title: Subtle alterations in PCNA-partner interactions severely impair DNA replication and repair publication-title: PLoS Biol doi: 10.1371/journal.pbio.1000507 – volume: 10 start-page: 29 year: 2011 ident: 2022061100595989400_bib48 article-title: Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-10-0778 – volume: 287 start-page: 14289 year: 2012 ident: 2022061100595989400_bib16 article-title: Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication publication-title: J Biol Chem doi: 10.1074/jbc.M112.353201 – volume: 134 start-page: 969 year: 2008 ident: 2022061100595989400_bib32 article-title: Mechanism of replication-coupled DNA interstrand crosslink repair publication-title: Cell doi: 10.1016/j.cell.2008.08.030 – volume: 81 start-page: 811 year: 2012 ident: 2022061100595989400_bib46 article-title: Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth publication-title: Mol Pharmacol doi: 10.1124/mol.112.077735 – volume: 123 start-page: 6108 year: 2001 ident: 2022061100595989400_bib29 article-title: Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor publication-title: J Am Chem Soc doi: 10.1021/ja0100120 – volume: 366 start-page: 799 year: 2012 ident: 2022061100595989400_bib39 article-title: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1110557 – volume: 9 start-page: 10 year: 2004 ident: 2022061100595989400_bib36 article-title: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib publication-title: Oncologist doi: 10.1634/theoncologist.9-suppl_3-10 – volume: 8 start-page: e61362 year: 2013 ident: 2022061100595989400_bib47 article-title: Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides publication-title: PLoS One doi: 10.1371/journal.pone.0061362 – volume: 3 start-page: e00149 year: 2015 ident: 2022061100595989400_bib24 article-title: Analysis of drug combinations: current methodological landscape publication-title: Pharmacol Res Perspect doi: 10.1002/prp2.149 – volume: 4 start-page: e1000110 year: 2008 ident: 2022061100595989400_bib21 article-title: Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair publication-title: PLoS Genet doi: 10.1371/journal.pgen.1000110 – volume: 131 start-page: 145 year: 1998 ident: 2022061100595989400_bib2 article-title: Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan publication-title: Cancer Lett doi: 10.1016/S0304-3835(98)00118-9 – volume: 14 start-page: 2313 year: 1997 ident: 2022061100595989400_bib9 article-title: Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair publication-title: Oncogene doi: 10.1038/sj.onc.1201072 – volume: 34 start-page: 51 year: 2006 ident: 2022061100595989400_bib26 article-title: Structural elucidation of hydroxylated metabolites of the isoflavan equol by gas chromatography-mass spectrometry and high-performance liquid chromatography-mass spectrometry publication-title: Drug Metab Dis doi: 10.1124/dmd.105.004929 – volume: 103 start-page: 19472 year: 2006 ident: 2022061100595989400_bib10 article-title: A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0604614103 – volume: 13 start-page: 533 year: 1993 ident: 2022061100595989400_bib1 article-title: Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer publication-title: Anticancer Res – volume: 361 start-page: 1164 year: 2009 ident: 2022061100595989400_bib41 article-title: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0905360 – volume: 74 start-page: 981 year: 2014 ident: 2022061100595989400_bib15 article-title: Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2574-x – volume: 37 start-page: 6400 year: 2009 ident: 2022061100595989400_bib31 article-title: The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links publication-title: Nucleic Acids Res doi: 10.1093/nar/gkp705 – volume: 87 start-page: 263 year: 2015 ident: 2022061100595989400_bib11 article-title: A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer publication-title: Mol Pharmacol doi: 10.1124/mol.114.093211 – volume: 53 start-page: 387 year: 2013 ident: 2022061100595989400_bib44 article-title: Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells publication-title: Mol Immunol doi: 10.1016/j.molimm.2012.09.012 |
| SSID | ssj0014104 |
| Score | 2.4419422 |
| Snippet | Proliferating cell nuclear antigen (PCNA) plays an essential role in regulating DNA synthesis and repair and is indispensable to cancer cell growth and... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 6053 |
| Title | The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29967249 https://www.proquest.com/docview/2063719395 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxJvykpG4rVzWju2mxyqiLEisEHSl3iI7cUTZNlmxzYVfz4ztpCnqisclivKwo5nJvPzNmJA3Fu04BjlgO1KGAEZmrC6YqsD2SV4WynqA7Jk-PZcfl2q52y7VV5ds7bj4ebCu5H-4CteAr1gl-w-c7QeFC3AO_IUjcBiOf83jWY3ZaGAdYt3jVhC-5nG-AseOrWpWoIN8_HVj1mu2CbvhuuOFR4BjnuBzdjYbuqhZVysZR43tgPq08fvWx_JNNHkI5sHUYMykBqR2r0vMRXv1bfU9NCqYt5vVRbNbhgqpH0ywDHMPPB3gOIK6PMH-vDLZ06ehJjrKjUgG2hFCp-Sw2lapzyDE0cZZ9oXBbOD6ieHzQP3LjeclGFE9EaHZ6W_9srtbN8ktAaGDLwBf9rAfhLXKgEMNc8WqLviCtwfnx27RccR91-WaeMT7JYt75G4MKOgsSMd9csPVD8jtTxEy8ZB8ACGhOyGhnZDQpqKG7gsJ3RcS2gsJRSF5RM7n7xbZKYv7Z7AiUXrLdGmEFVNtlUqqMi0LK601XGszsVxUHHvXKfgdJ07zslSJdcKIqpIp_NcGHkgek6O6qd1TQkurHdeFLcG0Szfh08KeQCThVApGSmoxIrIjTV7E5vK4x8k690GmSnMkbo7EzYG4OYdzIO6IjPvXLkN3lT-98Lqjew56EBe3TO2a9ioX4GvDdyVTNSJPAkP6ITsGPrv2znNyZyffL8jR9kfrXoK3ubWvvPj8ArVlddc |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Anticancer+Activity+of+a+First-in-class+Small-molecule+Targeting+PCNA&rft.jtitle=Clinical+cancer+research&rft.au=Gu%2C+Long&rft.au=Lingeman%2C+Robert&rft.au=Yakushijin%2C+Fumiko&rft.au=Sun%2C+Emily&rft.date=2018-12-01&rft.issn=1078-0432&rft.volume=24&rft.issue=23&rft.spage=6053&rft_id=info:doi/10.1158%2F1078-0432.CCR-18-0592&rft_id=info%3Apmid%2F29967249&rft.externalDocID=29967249 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |